Addressing potential role of magnesium dyshomeostasis to improve treatment efficacy for epilepsy: A reexamination of the literature. (26th October 2015)

• Record Type: Journal Article
• Authors: Osborn, Katie E.; Shytle, R. Douglas; Frontera, Alfred T.; Soble, Jason R.; Schoenberg, Mike R.
• Is Part Of: Journal of clinical pharmacology. Volume 56:Number 3(2016)
• Page Start: 260
• Page End: 265
• Publication Date: 2015-10-26
• Subjects: magnesium -- seizure -- epilepsy -- epileptogenesis -- metal ion -- electrolyte imbalance -- ketogenic diet; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.626
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Magnesium (Mg 2+ ) is an abundant mineral in the body serving many biochemical functions. Magnesium supplementation has been shown to raise seizure threshold in animal and human studies, but the etiological contribution of magnesium deficiency to the onset and maintenance of epilepsy, as well as the degree to which it impacts antiepileptic drug efficacy, remains poorly understood. This may be due, at least in part, to the inherent limitations of commonly used serum levels as a measure of functional magnesium status, as well as insufficient data regarding relative bioavailabilities of various magnesium salts and chelates for use with humans. To date, 1 randomized clinical trial has been conducted assessing Mg 2+ supplementation in epilepsy, and findings yielded promising results. Yet a notable dearth in the literature remains, and more studies are needed. To better understand the potential role of magnesium deficiency as a causal factor in epilepsy, more convenient and accurate measurement methods should to be developed and employed in randomized, controlled trials of oral magnesium supplementation in epilepsy. Findings from such studies have the potential to facilitate far‐reaching clinical and economic improvements in epilepsy treatment standards.